ONK Therapeutics Ltd

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vanda To Pay $100m For Rights To MS The

Intellia Therapeutics, Inc. is shifting focus to two in vivo gene editing programs set to enter pivotal development over the next year as the firm prepares for clinical milestones that could valida

2021 was largely defined by a lack of large-scale mergers and acquisitions, which gave way to more “bolt-on” or “tuck-in” deals aimed at strengthening R&D pipelines. As 2022 progresses, dealmakers wil

Intellia Therapeutics is to broaden its reach in oncology immunotherapy by combining its expertise in CRISPR gene-editing with allogeneic natural killer (NK) cell therapies being developed by ONK Th